Press release
Malmö, Sweden April 6, 2018
Introducing an advanced, easy to use, frontline test to rule out Coronary Artery Disease
The Acarix CADScor®System – on display and in focus at a key scientific symposium at DGK 2018
Acarix AB's (publ) ("Acarix") CADScor®System will be on display at DGK 2018 in Mannheim, Germany April 4-7. The CADScor®System has been validated clinically to rule out CAD with 97% negative predictive value and is now in use in selected clinics across Germany. At DGK 2018, both on the exhibition booth and at a late afternoon symposium, there will be opportunities to meet experts with experience from using the system in the clinic and to learn about a major new clinical study which started in February – Dan-NICAD II.
Dan-NICAD II will involve 1,500-2,000 patients with a low-to-intermediate likelihood of CAD from four Danish hospitals and is expected to further improve the CADScor®System 's already high, negative predictive value of 97% and provide health economic documentation supporting its use as a fast and safe frontline assessment to reduce patient referrals.
Acarix interim CEO Christian Lindholm commented: "Coronary Artery Disease affects more than 120 million people worldwide but the current diagnostic pathway, which can rapidly escalate to imaging and coronary angiography can be significantly improved. For a substantial proportion of patients presenting with chest pain symptoms to their general practitioner, CAD can be ruled out with our CADScor®System. Consequently, patients with symptoms unrelated to CAD do not have be referred to expensive and potentially harmful, further tests while only the patients who need further diagnostic tests get them."
Acarix CADScor®System is on display at Booth 328, DGK 2018
Contacts:
Acarix AB
Christian Lindholm, interim CEO, E-mail: secli@acarix.com, Phone: +46 705 118 333
Notes to editors:
Acarix, CADScor®System and cardiac sound measurement
Acarix was established in 2009 and is listed on Nasdaq First North Premier. Acarix's CADScor®System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen. Readings are obtained in less than 8 minutes. Safe and suitable for use in both out- and inpatient settings, the CADScor®System thus has the potential to play a major role in patient triage, avoiding the need for many patients to undergo stressful invasive diagnostic procedures.
See more at www.acarix.com.
Press photos: http://www.acarix.com/about-us/press-downloads/press-photos/
Recently published study: http://heart.bmj.com/content/early/2017/11/09/heartjnl-2017-311944
Invite to press conference
Date and time: April 6, 12.00 – 13.30, Venue: Room Ravel, Dorinth Hotel (immediately adjacent to the congress)
At the press conference, German cardiology experts will present current practice for diagnosing CAD, how the CADSCor®System works including live demonstration of the system as well as an overview of the re-imbursement situation in Germany.
Sign-up:Please sign up by sending an email to destw@acarix.com or call +49 172 823 4843 to announce your presence.
A press-kit consisting of Photos and short CV of participating experts, pictures of the device and background information including published scientific articles will be available.
Welcome!
Invite to Scientific symposium
Date and time: Friday April 6, at 17.30, Venue: Room 10
Acarix invites cardiologists and media to attend a scientific symposium in conjunction with DKG 2018 entitled "Ultrasensitive Phonokardiograpfie: Früher Auscchluss der koronaren Herzerkrankung durch akustische Analyse der Koronar-zirkulation". The symposium will be chaired by the German cardiology expert Christian Hamm and Morten Bøttcher, the Danish clinicians behind the innovation. Please announce your attendance to destw@acarix.com.
Welcome!
—
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Acarix AB via Globenewswire
